What's in Walvax Biotechnology Co., Ltd.'s pipeline?

Walvax Biotechnology Co., Ltd. has 7 drugs in our index: 2 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Walvax Biotechnology Co., Ltd.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Korea University Guro Hospital, University of Oxford, GlaxoSmithKline, Sanofi Pasteur, a Sanofi Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/walvax-biotechnology-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Walvax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief

Walvax Biotechnology Co., Ltd. pipeline: 2 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Yuxi Walvax MPV ACYW® vaccine	Yuxi Walvax MPV ACYW® vaccine	marketed
Sanofi Pasteur Menactra® vaccine	Sanofi Pasteur Menactra® vaccine	marketed	Conjugate vaccine	Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y)	Immunology / Infectious Disease
Pfizer PCV13	Pfizer PCV13	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)	Immunology / Infectious Disease
vaccination PPV23	vaccination PPV23	phase 3
vaccination PNEUMOVAX 23	vaccination PNEUMOVAX 23	phase 3	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)	Immunology / Infectious Disease
Walvax PCV13-TT	Walvax PCV13-TT	phase 3	Conjugate vaccine		Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 3
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Korea University Guro Hospital · 3 shared drug classes
University of Oxford · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
University of Minnesota · 2 shared drug classes
Sanofi · 2 shared drug classes
Epicentre · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Walvax Biotechnology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Walvax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/walvax-biotechnology-co-ltd. Accessed 2026-05-16.